MAIT cells possess MR1‐restricted tumor recognition ability; for instance, acute myeloid leukemia (AML) cells highly express MR1, making them a new target for chimeric antigen receptor (CAR)–MAIT therapy—preclinical models have shown that the tumor clearance rate can reach 60%. Here, MR1 is linked to acute myeloid leukemia.